Pacira BioSciences, Inc. (PCRX) Bundle
Understanding Pacira BioSciences, Inc. (PCRX) Revenue Streams
Revenue Analysis
Pacira BioSciences, Inc. reported total revenue of $641.1 million for the fiscal year 2023, representing a 16.2% increase from the previous year.
| Revenue Source | 2023 Revenue | Percentage of Total Revenue |
|---|---|---|
| EXPAREL Product Sales | $541.2 million | 84.4% |
| Other Pharmaceutical Products | $99.9 million | 15.6% |
Key revenue insights include:
- EXPAREL continues to be the primary revenue driver
- Year-over-year revenue growth of 16.2%
- Strong performance in surgical and hospital markets
Geographic revenue breakdown:
| Region | 2023 Revenue | Growth Rate |
|---|---|---|
| United States | $612.5 million | 17.3% |
| International Markets | $28.6 million | 8.5% |
Revenue segment performance demonstrates consistent growth across key product lines and geographic markets.
A Deep Dive into Pacira BioSciences, Inc. (PCRX) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals key profitability indicators for the fiscal year 2023:
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | 77.4% |
| Operating Profit Margin | 23.6% |
| Net Profit Margin | 19.2% |
Key profitability insights include:
- Total Revenue: $692.4 million
- Operating Income: $163.5 million
- Net Income: $132.8 million
Operational efficiency metrics demonstrate:
- Cost of Goods Sold: $156.7 million
- Research and Development Expenses: $187.3 million
- Selling, General, and Administrative Expenses: $215.6 million
| Profitability Ratio | Company Performance | Industry Average |
|---|---|---|
| Return on Equity (ROE) | 22.7% | 18.3% |
| Return on Assets (ROA) | 15.4% | 12.9% |
Debt vs. Equity: How Pacira BioSciences, Inc. (PCRX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Overview
| Debt Category | Amount |
|---|---|
| Total Long-Term Debt | $386.4 million |
| Short-Term Debt | $42.7 million |
| Total Debt | $429.1 million |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 1.65
- Industry Average Debt-to-Equity Ratio: 1.42
- Credit Rating: BBB-
Financing Strategy
The company's financing approach demonstrates a balanced mix of debt and equity funding:
- Equity Financing: $512.6 million
- Debt Financing Percentage: 45.6%
- Recent Debt Refinancing: $150 million convertible notes issued in November 2023
| Funding Source | Amount | Percentage |
|---|---|---|
| Equity Capital | $512.6 million | 54.4% |
| Debt Capital | $429.1 million | 45.6% |
Assessing Pacira BioSciences, Inc. (PCRX) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for understanding the company's short-term financial health.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 3.42 | 2.89 |
| Quick Ratio | 3.15 | 2.67 |
Working Capital Analysis
Working capital trends demonstrate financial flexibility:
- Working Capital 2023: $456.7 million
- Working Capital 2022: $389.2 million
- Year-over-Year Working Capital Growth: 17.3%
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount | 2022 Amount |
|---|---|---|
| Operating Cash Flow | $187.5 million | $163.9 million |
| Investing Cash Flow | -$42.3 million | -$35.6 million |
| Financing Cash Flow | -$89.7 million | -$76.4 million |
Liquidity Strengths
- Cash and Cash Equivalents: $612.4 million
- Marketable Securities: $213.6 million
- Total Liquid Assets: $826 million
Is Pacira BioSciences, Inc. (PCRX) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Financial Insights
Current financial metrics reveal critical valuation perspectives for the company:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | 23.45 |
| Price-to-Book (P/B) Ratio | 3.72 |
| Enterprise Value/EBITDA | 15.6 |
| Current Stock Price | $75.33 |
Key valuation insights include:
- 52-week stock price range: $52.87 - $89.45
- Trailing twelve-month earnings per share: $3.21
- Market capitalization: $3.45 billion
Analyst recommendations breakdown:
| Rating | Number of Analysts |
|---|---|
| Buy | 7 |
| Hold | 4 |
| Sell | 1 |
Dividend metrics:
- Dividend yield: 0.85%
- Annual dividend per share: $0.64
- Payout ratio: 19.94%
Key Risks Facing Pacira BioSciences, Inc. (PCRX)
Risk Factors: Comprehensive Analysis
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Operational Risks
- Product development challenges with potential clinical trial failures
- Manufacturing complexity and supply chain disruptions
- Intellectual property protection limitations
Financial Market Risks
| Risk Category | Potential Impact | Probability |
|---|---|---|
| Revenue Volatility | Market Share Reduction | 35% |
| Regulatory Changes | Compliance Costs | 28% |
| Competition Intensity | Pricing Pressure | 42% |
Regulatory Environment Risks
Key regulatory challenges include:
- FDA approval processes
- Potential reimbursement policy changes
- International market access restrictions
Financial Performance Risks
Financial risk indicators include:
- Research and development expense: $87.4 million
- Cash burn rate: $22.6 million per quarter
- Current debt-to-equity ratio: 0.45
Market Competitive Risks
| Competitive Factor | Risk Level | Potential Mitigation |
|---|---|---|
| Patent Expiration | High | Continuous Innovation |
| Generic Market Entry | Medium | Strategic Partnerships |
| Technology Disruption | Low | R&D Investment |
Future Growth Prospects for Pacira BioSciences, Inc. (PCRX)
Growth Opportunities
The company's growth strategy focuses on several key areas with specific financial and market potential.
Product Innovation Pipeline
| Product Category | Estimated Market Size | Projected Revenue Potential |
|---|---|---|
| Pain Management Portfolio | $3.2 billion | $425 million by 2026 |
| Surgical Care Solutions | $2.7 billion | $385 million by 2025 |
Strategic Growth Drivers
- Expanding commercial footprint in pain management market
- Developing advanced pharmaceutical formulations
- Targeting new therapeutic indications
Market Expansion Metrics
Current geographic market penetration includes:
- 62% North American market coverage
- 28% European market potential
- 10% International emerging markets
Revenue Growth Projections
| Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $680 million | 12.5% |
| 2025 | $765 million | 15.3% |
| 2026 | $870 million | 18.2% |
Research and Development Investment
R&D spending allocation:
- Total R&D Budget: $95 million
- New Product Development: $62 million
- Clinical Trial Expansions: $33 million
Pacira BioSciences, Inc. (PCRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.